Immusoft Secures FDA Orphan Drug Designation for ISP-002 in MPS II, a Progressive Lysosomal Storage Disease

Engineering B Cells With Immusoft’s Sean Ainsworth

Immusoft Receives FDA Fast Track Designation for ISP-001, a First-in-Class Engineered B Cell Therapy for MPS I

In a Major Breakthrough for Cell and Gene Therapy, Immusoft Has Re-dosed a Patient with ISP-001 in Its Lead Program for MPS I

Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells

Immusoft to Present Data at ASGCT 2025, Demonstrating Positive Results from the World’s First Engineered B Cell in a Human Clinical Trial

Immusoft Goes For Cell Therapy Plan ‘B’

Safety and Initial Activity of Autologous Human B Cells Genetically Engineered to Express Human Iduronidase Using the Sleeping Beauty Transposon System: Results from a First-in-Human Clinical Trial in Subjects with MPS I

Results from a First-in-Human Clinical Trial in Subjects with MPS I

Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium™ 2025

RARECast: Engineering B cells to Produce Therapeutic Proteins